Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
City of Hope Medical Center
Henry Ford Health System
Brown University
AstraZeneca
Georgetown University
AstraZeneca
M.D. Anderson Cancer Center
AstraZeneca
Memorial Sloan Kettering Cancer Center
University of Chicago
Johannes Gutenberg University Mainz
M.D. Anderson Cancer Center
Wake Forest University Health Sciences
AstraZeneca
Memorial Sloan Kettering Cancer Center
Swiss Cancer Institute
Intergroupe Francophone de Cancerologie Thoracique
Swiss Cancer Institute
Masonic Cancer Center, University of Minnesota
Swiss Cancer Institute
University of Birmingham
M.D. Anderson Cancer Center
University of Texas Southwestern Medical Center
Latin American Cooperative Oncology Group
Hoosier Cancer Research Network
University of British Columbia
Centre Leon Berard
Second Affiliated Hospital of Guangzhou Medical University
Sichuan University
University of Washington
Weill Medical College of Cornell University
AIO-Studien-gGmbH
University of Washington
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Hoosier Cancer Research Network
Sun Yat-sen University
Emory University